Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:05PM EDT
After hours:
| Previous close | 93.13 |
| Open | 93.20 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1400 |
| Day's range | 93.05 - 95.72 |
| 52-week range | 70.89 - 95.72 |
| Volume | |
| Avg. volume | 12,323,077 |
| Market cap | 238.745B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 17.23 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.76 (2.92%) |
| Ex-dividend date | 14 Jun 2022 |
| 1y target est | N/A |
- Business Wire
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
RAHWAY, N.J., June 27, 2022--LYNPARZA® Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
- Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
RAHWAY, N.J., June 24, 2022--European Commission Approves KEYTRUDA as Adjuvant Treatment for Adult & Adolescent Patients With Stage IIB or IIC Melanoma After Complete Resection
- Business Wire
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
RAHWAY, N.J., June 22, 2022--CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ as an Option for Pneumococcal Vaccination in Infants and Children
© 2022 Yahoo. All rights reserved.
